United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 21,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 21,000 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $478.60, for a total transaction of $10,050,600.00. Following the sale, the chief financial officer owned 8,142 shares of the company’s stock, valued at $3,896,761.20. This represents a 72.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, December 1st, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $479.99, for a total transaction of $10,079,790.00.
• On Monday, November 24th, James Edgemond sold 21,000 shares of United Therapeutics stock. The shares were sold at an average price of $473.64, for a total transaction of $9,946,440.00.
• On Monday, November 17th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $470.36, for a total value of $9,877,560.00.
• On Monday, November 10th, James Edgemond sold 21,000 shares of United Therapeutics stock. The shares were sold at an average price of $452.07, for a total value of $9,493,470.00.
• On Tuesday, November 4th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $436.09, for a total transaction of $9,157,890.00.

United Therapeutics Trading Down 0.7%

Shares of United Therapeutics stock traded down $3.15 during trading on Tuesday, reaching $476.36. The company’s stock had a trading volume of 299,097 shares, compared to its average volume of 580,494. The company has a 50-day moving average price of $454.01 and a two-hundred day moving average price of $369.93. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $492.62. The firm has a market cap of $20.51 billion, a PE ratio of 18.05, a P/E/G ratio of 4.86 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same period in the prior year, the company earned $6.39 earnings per share. The business’s revenue was up 6.8% compared to the same quarter last year. On average, analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. LPL Financial LLC boosted its stake in shares of United Therapeutics by 77.3% during the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock worth $7,783,000 after acquiring an additional 11,007 shares in the last quarter. XTX Topco Ltd purchased a new position in United Therapeutics in the 1st quarter valued at approximately $313,000. US Bancorp DE raised its holdings in United Therapeutics by 12.2% during the first quarter. US Bancorp DE now owns 1,971 shares of the biotechnology company’s stock worth $608,000 after purchasing an additional 215 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in United Therapeutics by 27.5% during the first quarter. PNC Financial Services Group Inc. now owns 4,059 shares of the biotechnology company’s stock worth $1,251,000 after purchasing an additional 875 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in United Therapeutics by 0.3% during the first quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company’s stock worth $1,374,001,000 after purchasing an additional 15,312 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on UTHR shares. Royal Bank Of Canada increased their price target on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Weiss Ratings restated a “buy (b-)” rating on shares of United Therapeutics in a research report on Monday, December 1st. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Jefferies Financial Group reiterated a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Finally, Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $505.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.